Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes (2014)

Peer-Reviewed Study · Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A, et al. · November 1, 2014

Kanterman J et al., 2014-11-01: Human and mouse study of colorectal cancer chemotherapy finding that regimen matters: FOLFOX reduced immunosuppression while FOLFIRI increased MDSC-driven suppression and worsened outcomes.

some conventional colorectal cancer chemotherapy supports the immunosuppressive tumor microenvironment. A FOLFOX combined therapy reduced immunosuppression, whereas a FOLFIRI combined therapy enhanced immunosuppression.

Abstract

Kanterman J et al., 2014-11-01: Human and mouse study of colorectal cancer chemotherapy finding that regimen matters: FOLFOX reduced immunosuppression while FOLFIRI increased MDSC-driven suppression and worsened outcomes. This is the honest middle: it supports the book's mechanism for one regimen (FOLFIRI, 5-FU plus irinotecan) while contradicting any blanket statement, since FOLFOX went the other way. Comparator: FOLFOX vs FOLFIRI vs untreated. Funder/COI not in the abstract. Pairs directly against CHB-29, which used 5-FU alone.